Valuation: Atrion Corporation

Market Cap 809M 723M 674M 613M 1.15B 78.39B 1.16B 8.1B 3.17B 39.84B 3.04B 2.97B 128B P/E 2022
28.6x
P/E 2023 34.4x
Enterprise Value 803M 717M 669M 608M 1.14B 77.81B 1.16B 8.04B 3.14B 39.54B 3.02B 2.95B 127B EV / Sales 2022
5.27x
EV / Sales 2023 3.9x
Free-Float
50.88%
Yield 2022
1.47%
Yield 2023 2.3%
3 years 274.98
Extreme 274.98
503.24
5 years 274.98
Extreme 274.98
805.62
10 years 274.98
Extreme 274.98
948.03
Manager TitleAgeSince
Corporate Secretary 53 21/08/2024
Director TitleAgeSince
Director/Board Member 53 21/08/2024
Date Insider Type Main position Quantity % Market Cap. Importance
21/08/24 Issuer sale

Director

2,991 0.1699%
21/08/24 Issuer sale

Chief Executive Officer

98,614 5.6032%
21/08/24 Issuer sale

Director

499 0.0284%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%-.--%-.--%+13.84% 809M
-0.24%+1.86%-26.65%+1.66% 170B
+2.62%+1.52%-10.34%+15.28% 112B
+0.57%+1.47%-26.20%+4.18% 106B
-2.49%-1.11%-48.69%-12.84% 73.6B
+1.29%+3.73%+3.46%+74.79% 61.32B
+0.12%+3.62%+12.66%+65.87% 52.89B
+1.44%+2.63%-5.76%-30.36% 49.78B
+1.28%-0.89%-18.54%+15.06% 40.43B
+0.13%-2.11%+24.54%+1.43% 31.85B
Average +0.48%+1.16%-9.55%+14.89% 69.96B
Weighted average by Cap. +0.49%+1.54%-16.36%+12.47%

Financials

2022 2023
Net sales 184M 164M 153M 139M 261M 17.77B 264M 1.84B 718M 9.03B 689M 674M 29.04B 169M 151M 141M 128M 241M 16.4B 243M 1.69B 662M 8.33B 636M 622M 26.8B
Net income 35.01M 31.26M 29.16M 26.49M 49.85M 3.39B 50.34M 350M 137M 1.72B 131M 129M 5.54B 19.41M 17.33M 16.17M 14.69M 27.64M 1.88B 27.91M 194M 75.94M 955M 72.88M 71.3M 3.07B
Net Debt -25.21M -22.51M -21M -19.08M -35.9M -2.44B -36.25M -252M -98.63M -1.24B -94.66M -92.6M -3.99B -6.02M -5.37M -5.01M -4.55M -8.57M -583M -8.65M -60.17M -23.53M -296M -22.59M -22.1M -952M
Projected Income Statement - Annual - Atrion Corporation
Logo Atrion Corporation
Atrion Corporation develops and manufactures products, primarily for medical applications. The Company's medical products are used in a number of fields including fluid delivery, cardiovascular, and ophthalmic applications. It has developed a variety of proprietary valves designed to precisely fill, hold, and release and/or remove controlled amounts of fluids, including blood and drugs, or gasses on demand for use in areas such as intubation, intravenous, catheter, and other applications in fields including anesthesia and oncology. The core of its cardiovascular products is its Myocardial Protection System, a technology that is the only open-heart surgery system that delivers to the heart essential fluids and medications, mixes critical drugs, and controls temperature, pressure, and other important variables. The Company also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults.
Employees
712
  1. Stock Market
  2. Stocks
  3. ATRI Stock